Skip to main content

Security report for novartis.gr

Novartis Greece · Healthcare · Greece

Low risk. 3 critical or high findings in Security headers and SSL/TLS.

Security score

79/100

Risk levelLow

0–100, higher is better. How it is calculated

Novartis Greece operates as a regional branch of the global pharmaceutical leader Novartis AG, focusing on redefining medical practice through innovative scientific data and digital technologies. The company targets improving and extending human lives by developing pioneering therapies addressing significant medical needs. The website reflects a mature digital presence with localized Greek content, professional design, and comprehensive compliance with privacy and cookie regulations. Technically, the site is built on Drupal CMS, integrates modern analytics and marketing tools, and demonstrates good performance and accessibility standards. Security posture is strong with HTTPS enforcement, security headers, and no visible vulnerabilities, although public security policies and incident response contacts are not explicitly published. The absence of WHOIS data is a notable anomaly but does not undermine the site's legitimacy given the corporate branding and content quality. Overall, Novartis Greece's website is a trustworthy, professional platform supporting its business objectives in the healthcare sector.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching novartis.gr

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
52
Security headers
65
Email security
85
DNS health
85
Network security
100
GDPR outside view
88
Average
79

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Novartis Greece holds a strong market position as part of a top global pharmaceutical company, leveraging innovation and digital transformation to serve medical needs in Greece. The business model centers on pharmaceutical research, development, and commercialization of advanced therapies. The company targets healthcare professionals, patients, and stakeholders interested in medical advancements. The website's structured data and social media presence reinforce its corporate identity and outreach. The use of multiple analytics and marketing tools indicates a data-driven approach to customer engagement and market intelligence. The lack of visible subsidiaries or partner domains suggests a focused regional operation under the global Novartis umbrella.

Security posture

The website demonstrates a mature security posture with enforced HTTPS, presence of key security headers, and secure form implementations. No exposed sensitive data or vulnerable libraries were detected in the HTML content. However, the absence of a public security policy page, incident response contacts, and vulnerability disclosure mechanisms indicates room for improvement in transparency and incident readiness. Compliance with GDPR is evident through privacy and cookie policies with consent mechanisms. The integration of third-party analytics and marketing scripts is managed with user consent, mitigating privacy risks. Overall, the security maturity is good but could be enhanced by publishing explicit security governance documents and contact channels.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and commitments.
  2. Provide clear incident response contact information to improve transparency and trust.
  3. Implement and publicize a vulnerability disclosure program or security.txt file.
  4. Enhance data protection officer contact visibility to comply fully with GDPR transparency requirements.
  5. Regularly review and audit third-party scripts to minimize potential security risks.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Novartis Greece
Description
Σκοπός μας είναι να επαναπροσδιορίζουμε την ιατρική πρακτική, για να βελτιώσουμε και να επεκτείνουμε τις ζωές των ανθρώπων.Ως κορυφαία παγκόσμια φαρμακευτική εταιρεία, αξιοποιούμε καινοτόμα επιστημονικά δεδομένα και ψηφιακές τεχνολογίες για την ανάπτυξη πρωτοποριακών θεραπειών που κάνουν τη διαφορά σε τομείς, όπου υπάρχει μεγάλη ιατρική ανάγκη.
Key services
development of innovative therapies, scientific research, digital technology integration
Content quality
excellent
Branding
consistent

Technology

Stack
Drupal CMS, Google Tag Manager, Litepicker (date picker), Crazy Egg, TikTok Pixel, AddToAny
Frameworks
Drupal
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Content Security Policy present
  • No exposed sensitive data in HTML
  • Secure forms with autocomplete off

Analytics and tracking

Services
Google Analytics (via GTM), Crazy Egg, TikTok Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Ad networks
Crazy Egg
Tracking pixels
TikTok Pixel
Marketing tools
AddToAny
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenge.
  2. Content is professional, well-structured, and localized in Greek.
  3. Strong presence of privacy and cookie policies with consent mechanisms.
  4. Use of multiple third-party analytics and marketing tools with consent.
  5. No exposed sensitive information or security misconfigurations detected.
  6. WHOIS data is missing, which is unusual but does not detract from site legitimacy.
  7. Social media presence is consistent with a global pharmaceutical company.
Technical notes

Notes

The website is built on Drupal CMS, a robust and widely used content management system, ensuring scalability and security. It employs modern JavaScript libraries and integrates analytics and marketing tools such as Google Tag Manager, Crazy Egg, TikTok Pixel, and AddToAny for social sharing. The site is mobile-optimized with good accessibility features and SEO meta tags, including Open Graph and JSON-LD structured data for enhanced search engine visibility. Performance is moderate, likely influenced by multiple third-party scripts. There is no explicit hosting provider information, but the use of CDN and external services suggests a distributed infrastructure. Technical risks are minimal, with no visible outdated or vulnerable components in the provided HTML content.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with novartis.gr. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review novartis.gr.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.